Investment Focus

MPH invests in seed and early-stage biotech companies based principally in North America and Europe, usually as part of an investment syndicate with other leading VC firms.

Therapeutic & Technology Priority Areas

MPH invests in companies developing novel therapeutics, platform technologies, diagnostics, and vaccines. MPH is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.